Home
overview

SMi are very pleased to present its inaugural event on Allergies

Allergies represent one of the fastest growing chronic diseases. There is still no cure. There is increasing focus on the ways to treat allergies and less on the symptoms of allergic diseases. Companies are taking different approaches to control allergies in a more effective way.

The market for allergies is set to reach $14.7 billion by 2015. As companies look to develop different compounds and antibodies to treat allergies, our 2014 event marks the path forward in terms of allergies within personalised medicines and beyond.

The conference will examine novel approaches in the treatment of allergy, advances in the understanding of allergic pathophysiology: therapeutic implications, food allergies - what is new? The future of allergen-specific immunotherapy and challenges in allergy prevention, diagnosis and drug development will be explored.
 

  • Evaluate new breakthroughs in allergy treatment
  • Gain understanding into guidance on development novel therapeutics
  • Developing immunotherapies that are better today
  • Exclusive case study on the success of peanut allergy trials

This event is aimed at Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in:
Immunotherapy Drug Discovery
Allergy Medicine
Allergy Pharmacology
Immunotherapy
Research Immunology
Pharmacology
Immunotherapy Licensing
Inflammation and Autoimmunity
Immunology
Allergy Cell Biology
Allergy Therapeutics
Allergy Devices
Medical Devices
Inflammation Discovery
Allergy Medicine Regulation



 

Conference programme

8:30 Registration and coffee

9:00 Chairman's opening remarks

Daphne Tsitoura

Daphne Tsitoura, Senior Medical Director, Clinical Drug Development / Discovery Medicine, GlaxoSmithKline

Philip Ashton-Rickardt

Philip Ashton-Rickardt, Chair in Immunology, Imperial College Administration

9:10 Toll-like receptor agonists: a new therapeutic tool for allergies

Daphne Tsitoura

Daphne Tsitoura, Senior Medical Director, Clinical Drug Development / Discovery Medicine, GlaxoSmithKline

  • Rationale for the use of TLR agonists in the treatment of immunological disorders
  • Clinical investigations in allergy
  • Challenges and next steps
  • 9:50 Preclinical advances in Atopic Dermatitis

    Ian Strickland

    Ian Strickland, Research Scientist, MedImmune

  • Mechanisms relevant to atopic dermatitis
  • New animal models of disease
  • Clinical progress in MedImmune asthma portfolio and potential value of current asthma assets for atopic dermatitis
  • 10:30 Morning coffee

    11:00 Targeting inflammation in allergic asthma

    Myriam  Cherif

    Myriam Cherif, Medical Scientific Liaison – Critical Care, Novartis

     

  • ·          Targeting inflammation in allergic asthma: new and old biomarkers
  • ·          Towards personalised medicine in asthma: myth or reality?
  • ·          The changing landscape in the treatment of asthma
  • 11:40 Current status of food allergy management

    Chiara Nembrini

    Chiara Nembrini, Research Scientist in Allergy, Nestle Research Center

  • Our approaches to managing allergies globally
  • Exploring the challenges in food immunotherapy
  • Developing advances in food allergy treatment
     
  • 12:20 Networking lunch

    13:40 The puzzle of non-allergic eosinophilic inflammation in the respiratory tract

    Glenis Scadding

    Glenis Scadding, Hon. Consultant Allergist and Rhinologist, Royal National Throat, Nose and Ear Hospital, London

     

  • ·          Evaluating non-allergic rhinitis comprising different conditions, not all inflammatory
  • ·          Analysing the incomplete understanding of allergic rhinitis
  • ·          The role of eosinophilic inflammation in non-allergic disease
  • ·          Discussion of the aetiopathology of non-allergic eosinophilia in the upper airway and non-allergic lower airways disease
     
  • 14:20 Targeting memory Th2 cells in allergic diseases. From Model to Man

    Philip Ashton-Rickardt

    Philip Ashton-Rickardt, Chair in Immunology, Imperial College Administration

     

    ·          Emerging role of memory Th2 cells in allergy
    ·          Targeting memory Th2 cells
    ·          Case study on a new target for the elimination of memory Th2 cells

    15:00 Afternoon tea

    15:30 Allergen-specific immunotherapy: current and novel approaches

    Guy  Scadding

    Guy Scadding, Clinical Research Fellow, National Heart and Lung Institute

     

  • ·          Who should we select for allergen-specific immunotherapy?
  • ·          Current treatment options and their limitations
  • ·          Novel approaches to improve safety and efficacy
  • 16:10 Mechanisms of SLIT: the role of dendritic cells

    Kayhan Nouri-Aria

    Kayhan Nouri-Aria, Lecturer, Allergy and Clinical Immunology, Imperial College London

  • ·          SLIT – a safe, injection free and alternative to SCIT
  • ·          Focus on the sublingual region – transporting the allergen to the local lymph node by DCs
  • ·          How to facilitate tolerogenic immune responses during SLIT
  • 16:40 Chairman's closing remarks

    8:30 Registration and coffee

    9:00 Chairman's opening remarks

    Daphne Tsitoura

    Daphne Tsitoura, Senior Medical Director, Clinical Drug Development / Discovery Medicine, GlaxoSmithKline

    Philip Ashton-Rickardt

    Philip Ashton-Rickardt, Chair in Immunology, Imperial College Administration

    9:10 Advances with recombinant allergy vaccines: the future of allergy immunotherapy

    Rainer  Henning

    Rainer Henning, CEO, Biomay AG

  • ·          Identify the shortcomings of specific allergy immunotherapy as practiced today
  • ·          Discussion of the principles of recombinant or synthetic allergy vaccines
  • ·          Discussion of preclinical efficacy, available clinical results and future clinical impact of these vaccines
  • 9:50 Passive immunisation with allergen-specific IgG antibodies for the treatment and prevention of allergy

    Birgit Linhart

    Birgit Linhart, Department of Pathophysiology and Allergy Research, University Of Vienna

     

  • ·          Role of allergen-specific IgG antibodies for treatment and prevention of allergy and understanding the mechanisms of action
  • ·          Available allergen-specific antibodies and technologies for generation allergen-specific IgG antibodies for treatment and prevention
  • ·          Strategies for therapy and prevention of allergy based on allergen-specific IgG
     
  • 10:30 Morning coffee

    11:00 Peanut allergy treatment - a success

    Pam Ewan

    Pam Ewan, Consultant Allergist, Addenbrookes Hospital

  • The impact of peanut allergy
  • Discussion of findings during the immunotherapy trials 
  • 11:40 Prevention of food allergies: how to deal with the proteins of the future

    Babs Fabriek

    Babs Fabriek, Senior Scientist, TNO

  • ·          How to assess the risk of novel proteins
  • ·          How we can rank the allergenic proteins in potency
  • ·          Exploring the prevalence of known allergies in the population
  • 12:20 Networking lunch

    13:30 Case study: Allergy prevention in an era of personalised medicine

    Alf Lindberg

    Alf Lindberg, Chief Scientific Officer, Swecure

     

  • ·          Gaining an insight into allergy prevention techniques and methodologies
  • ·          Developing our work from the pre-clinical through to the clinical stages
  • ·          Conclusions discussed and the path forward
  • 14:10 Advances in allergy diagnostics: moving from the bench to the clinic

    Suranjith Seneviratne

    Suranjith Seneviratne, Consultant in Clinical Immunology and Allergy, Royal Free Hospital

     

  • ·          Discussion of recent findings in allergy diagnostics
  • ·          How do they impact on patient management
  • ·          Potential future developments in the field
  • 14:50 Insights for the clinical development of drugs for allergic diseases

    Juan Gispert

    Juan Gispert, Senior Medical Director and Chair Centre of Excellence, Quintiles

  • ·          How to improve study designs, pharmacological and regulatory perspective
  • ·          Tips and pitfalls in the recruitment of Allergic patients
  • ·          Ethical concerns in allergy trials
     

     

     
  • 15:30 Chairman's closing remarks

    15:40 Afternoon tea

    +

    FEATURED SPEAKERS

    Alf Lindberg

    Alf Lindberg

    Chief Scientific Officer, Swecure
    Daphne Tsitoura

    Daphne Tsitoura

    Senior Medical Director, Clinical Drug Development / Discovery Medicine, GlaxoSmithKline
    Professor Rudolf Valenta

    Professor Rudolf Valenta

    , Department of Pathophysiology and Allergy Research

    Alf Lindberg

    Chief Scientific Officer, Swecure
    Alf Lindberg

    Babs Fabriek

    Senior Scientist, TNO
    Babs Fabriek

    Birgit Linhart

    Department of Pathophysiology and Allergy Research, University Of Vienna
    Birgit Linhart

    Chiara Nembrini

    Research Scientist in Allergy, Nestle Research Center
    Chiara Nembrini

    Daphne Tsitoura

    Senior Medical Director, Clinical Drug Development / Discovery Medicine, GlaxoSmithKline
    Daphne Tsitoura

    Glenis Scadding

    Hon. Consultant Allergist and Rhinologist, Royal National Throat, Nose and Ear Hospital, London
    Glenis Scadding

    Guy Scadding

    Clinical Research Fellow, National Heart and Lung Institute
    Guy  Scadding

    Ian Strickland

    Research Scientist, MedImmune
    Ian Strickland

    Juan Gispert

    Senior Medical Director and Chair Centre of Excellence, Quintiles
    Juan Gispert

    Kayhan Nouri-Aria

    Lecturer, Allergy and Clinical Immunology, Imperial College London
    Kayhan Nouri-Aria

    Myriam Cherif

    Medical Scientific Liaison – Critical Care, Novartis
    Myriam  Cherif

    Pam Ewan

    Consultant Allergist, Addenbrookes Hospital
    Pam Ewan

    Philip Ashton-Rickardt

    Chair in Immunology, Imperial College Administration
    Philip Ashton-Rickardt

    Professor Rudolf Valenta

    , Department of Pathophysiology and Allergy Research
    Professor Rudolf Valenta

    Rainer Henning

    CEO, Biomay AG
    Rainer  Henning

    Suranjith Seneviratne

    Consultant in Clinical Immunology and Allergy, Royal Free Hospital
    Suranjith Seneviratne

    Workshops

    Maximising efficiencies in clinical development in allergy
    Workshop

    Maximising efficiencies in clinical development in allergy

    Holiday Inn Regents Park
    8th July 2014
    London, United Kingdom

    Interview with Nestle

    Download

    Interview with Dr. Kayhan Nouri-Aria

    Download

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.